2,3-Butanediol, 1-benzyloxy-

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-Butanediol, 1-benzyloxy-
• 英文别名: 1-phenylmethoxybutane-2,3-diol
• 化学式: C₁₁H₁₆O₃
• 分子量: 196.24
• InChiKey: ANKPCTWGDMEUSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Aromatic diols
  申请人：GLAXO GROUP LIMITED

  公开号：EP0359290A1

  公开（公告）日：1990-03-21

  Compounds are disclosed of formula Where R¹ is halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, hydroxyl, cyano, nitro and -NR³R⁴ where R³ and R⁴ is each a hydrogen atom or C₁₋₄ alkyl, and R² is hydrogen or a substituent as defined for R¹. Process for the preparation of the compounds are described.

  公开了式 其中 R¹ 为卤素、C₁₋₄ 烷基、C₁₋₄ 烷氧基、羟基、氰基、硝基和 -NR³R⁴ 其中 R³ 和 R⁴ 各为氢原子或 C₁₋₄ 烷基，R² 为氢或 R¹ 所定义的取代基。描述了化合物的制备过程。
• Use of benzodioxinopyrrole derivatives in the manufacture of a medicament for the treatment of anxiety
  申请人：GLAXO GROUP LIMITED

  公开号：EP0407016A2

  公开（公告）日：1991-01-09

  The use of the compound of formula (II) or a physiologically acceptable salt or hydrate thereof in the treatment, relief or prevention of the effects of anxiety The compound of formula (II) is described in UK Published Patent Application No. 2157691A. The preferred compound for use in this indication is (±)-trans-5-­fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]-benzodioxino[2,3-c]- pyrrole, especially in the form of its hydrochloride salt.

  式(II)化合物或其生理上可接受的盐或水合物在治疗、缓解或预防焦虑症中的应用 英国公开专利申请第 2157691A 号中描述了式 (II) 化合物。 用于本适应症的优选化合物是(±)-反式-5-氟-2,3,3a,9a-四氢-1H-[1,4]-苯并二恶烷并[2,3-c]-吡咯，特别是其盐酸盐形式。
• Medicaments for the treatment of sexual disorder
  申请人：GLAXO GROUP LIMITED

  公开号：EP0460912A2

  公开（公告）日：1991-12-11

  The use of a compound of formula I wherein R is a hydrogen atom or a group selected from C₁₋₆alkyl (optionally substituted by C₃₋₇cycloalkyl), C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₇cycloalkyl, aralkyl (in which the alkyl moiety contains 1-5 carbon atoms) and -CHO; R¹ and R², which may be the same or different, represent a hydrogen atom, a halogen atom or a group selected from C₁₋₄alkyl, C₁₋₄alkoxy, hydroxyl, cyano, nitro and -NR³R⁴ where R³ and R⁴ is each a hydrogen atom or a C₁₋₄alkyl group and X is an oxygen atom or a group -CH₂₋; or a physiologically acceptable salt or hydrate thereof for treating, relieving or preventing the effects of sexual dysfunction. Preferred compounds include trans-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4] benzodioxino [2,3-c]pyrrole and trans-5-fluoro-1,2,3,3a,9,9a-hexahydro[1] benzopyrano [2,3-c]pyrrole. Conditions that may be treated in this manner include, in the case of the male, erectile inadequacy and, in the case of the female, sexual arousal disorder.

  使用式 I 的化合物 其中 R 是氢原子或选自 C₁₋₆ 烷基（任选被 C₃₋₇ 环烷基取代）、C₃₋₆ 炔基C₃₋₆炔基、C₃₋₇环烷基、芳烷基（其中烷基含有 1-5 个碳原子）和 -CHO； R¹ 和 R²（可以相同或不同）代表氢原子、卤素原子或选自 C₁₋₄、C₁₋₄ 烷氧基、羟基、氰基、硝基和 -NR³R⁴ 的基团，其中 R³ 和 R⁴ 各为氢原子或 C₁₋₄ 烷基。 和 X 是氧原子或基团 -CH₂₋； 或其生理上可接受的盐或水合物 用于治疗、缓解或预防性功能障碍。 首选化合物包括反式-5-氟-2,3,3a,9a-四氢-1H-[1,4]苯并二噁[2,3-c]吡咯和反式-5-氟-1,2,3,3a,9,9a-六氢[1]苯并吡喃[2,3-c]吡咯。 可以用这种方法治疗的疾病包括男性的勃起不足和女性的性唤起障碍。
• Vaccines against Streptococcus pneumoniae serotype 5
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US10596272B2

  公开（公告）日：2020-03-24

  The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit of Streptococcus pneumoniae serotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae serotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

  本发明涉及与肺炎链球菌血清 5 型荚膜多糖重复单元有关的通式（I）的定义明确的合成糖类及其共轭物。所述共轭物和含有所述共轭物的药物组合物可用于预防和/或治疗与肺炎链球菌相关的疾病，更具体地说，可用于预防和/或治疗与肺炎链球菌血清 5 型相关的疾病。此外，通式（I）的合成糖类可作为免疫学试验中的标记物，用于检测针对肺炎链球菌的抗体。
• Heterocyclic amino compounds
  申请人：GLAXO GROUP LIMITED

  公开号：EP0162593B1

  公开（公告）日：1990-08-16